Rennova Health, Inc. · OTC:RNVA
Rennova Health — Investor Presentation (July 2017)
21 slides from Rennova Health's investor presentation, Jul 11, 2017
Slide 1: Diagnostics and Supportive Software Solutions to Healthcare Providers
Nasdaq: Common stock RNVA Warrants (July 2021) RNVAZ Diagnostics and Supportive Software Solutions to Healthcare Providers July 2017
Slide 2: Forward Looking Statements and Non-GAAP Information
This presentation includes forward - looking statements about Rennova Health’s anticipated results that involve risks and uncertainties . Some of the information contained in this presentation, including statements as to industry trends and plans, objectives, expectations and strategy for the busine
Slide 3: We are Rennova Health: Healthcare is Being Transformed
We are Rennova Health 3 Healthcare is Being Transformed
Slide 4: • Five - year history of operations in clinical laboratory space • Toxicology •
• Five - year history of operations in clinical laboratory space • Toxicology • Clinical • Genetic testing including pharmacogenomics and oncology • Three years in software development for the medical sector • Proprietary lab ordering and reporting • Lab information systems • Electronic Health Recor
Slide 5: • The diagnostics sector has changed dramatically in the last few years • Paper
• The diagnostics sector has changed dramatically in the last few years • Paper records and faxes meant different vendors to a medical provider could function side by side without communication • Electronic platforms and integration have created a need for providers of solutions to communicate effic
Slide 6: Rennova Offers a Single Source Solution for Medical Providers
Clinical Lab S ervices Revenue Cycle Management Software S olutions Single Source Solution 5 Clinical Laboratories Integrated Medical Billing Company Creates opportunity for future provision of financial services Proprietary Lab ordering and reporting Laboratory Information System (LIS) EHR / Practi
Slide 7: Recent Developments: Clinical Laboratory Operations Segment
Clinical Laboratory Operations Segment • Transitioned from focus on toxicology to expanded menu of clinical diagnostics • Acquired CollabRx and Genomas for their technology in the oncology interpretation market and the pharmacogenomics testing sector • Hospital acquisition completed in January 2017
Slide 8: Supportive Software Solutions Segment
Supportive Software Solutions Segment • Our integrated software solution creates a much more sustainable relationship with our customers • EHR product launched in substance abuse sector last quarter 2015 Revenue Cycle Management • We launched a specialized division to provide medical billing service
Slide 9: Drug and Alcohol Rehabilitation and Pain Management Markets
Drug and Alcohol Rehabilitation • Total Market Size – estimated at $35 Billion* • Large and growing number of facilities in a fragmented market • Between 14,500 to 16,700 outpatient clinics* Market growth from high demand: • Over 23 million Americans are addicted to alcohol and other drugs** • The n
Slide 10: Rennova Health Licensing Map
10 Rennova Health Licensing Map
Slide 11: Our Payers
• Initiated Medicaid Licensing & Third Party Payer Initiative in December 2015 o Applied for Medicaid Licenses in 34 States o We possess Medicaid Licenses in 28 States • Current Third Party Insurance Payer Contracts o Blue Shield of California o Coventry (National Contract) o Corvel o Multiplan o Pr
Slide 12: History in Numbers
12 History in Numbers 41,889 59,429 37,877 6,245 14,775 19,749 1,386 (25,216) (30,000) (20,000) (10,000) 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 2013 2014 2015 2016 Adjusted Revenues Adjusted EBITDA ($000’s)
Slide 13: Select Income Statement Items
13 Select Income Statement Items (in thousands) 2013 2014 2015 2016 GAAP Net Revenue 41,889$ 57,928$ 18,393$ 5,245$ Reserve for Aged Accounts Receivable - 1,501 19,494 1,000 Adjusted Revenues 41,889$ 59,429$ 37,887$ 6,245$ GAAP Pretax Income (Loss) 13,829$ 15,382$ (44,991)$ (32,400)$ Depreciation an
Slide 14: Strategy
ee | A® van Tor eos TF k ae aol Strategy a | Saf Tt ee
Slide 15: The Long Term Strategy
Create a sustainable relationship with our customers to grow recurring revenue and provide value to our shareholders How? Build from a toxicology - focused company to: 1. A significant and diverse diagnostics business including the provision of “needed services” from ownership of hospitals and Dr’s
Slide 16: 2017 Goals
• Strengthen Core Diagnostic Business o Plan to o pen our 1 st hospital o Continue to capitalize on the disruption in toxicology sector o Increase Clinical testing o Grow Pharmacogenomics testing with Genomas o Launch DTC (Direct to Consumer) testing o Consider opportunities for acquisition of addit
Slide 17: Our goal in numbers
• We believe that we ca n achieve the following revenues for 2018 o $600K per month for toxicology and clinical diagnostics o $400K per month for software and RCM related revenue o $1M per month from our hospital in TN Subject to acquisition o $800K per month from Dr’s practices o $1M per month from
Slide 18: Management Team
Seamus Lagan CEO • 20 years experience in the restructuring, development and management of startup and small companies Victoria Nemerson, Esq. General Counsel • 25 years experience as a compliance and healthcare attorney Scott Jenkins CEO of Genetic Testing Division • Prior CEO Positions at Alchemis
Slide 19: Board of Directors (July 2017)
Seamus Lagan CEO • 20 years experience in the restructuring, development and management of startup and small companies • Founder, investor and shareholder Christopher Diamantis Director • Chairman and CEO of Integrated Financial Settlements, Inc., a structured settlement consulting firm. Trevor Lang
Slide 20: Capitalization Table
20 Capitalization Table 11 - Jul - 17 Common Shares Issuable upon Exercise/ Conversion Common Stock 13,908,360 13,908,360 Series G Preferred Stock 215 15,926 Series H Preferred Stock 60 153,847 Sabby Healthcare New Debenture 7,130,000 18,282,051 Sabby Bridge Exchange Debenture 2,464,500 6,319,231 Sa
Slide 21: • Five - year history of operations in clinical laboratory space • Toxicology •
• Five - year history of operations in clinical laboratory space • Toxicology • Clinical • Genetic testing including pharmacogenomics and oncology • Three years in software development for the medical sector • Proprietary lab ordering and reporting • Lab information systems • Electronic Health Recor